1. Generics Bulletin
  2. >>Business
  3. >>Earnings

Sandoz Champions Stability As It Returns To Growth In Q2

Investments In Biosimilars Will Spearhead Financial Goals

 
• By Dean Rudge

Sandoz enjoyed both top- and bottom-line growth in the second quarter, as the Novartis company rebounded from a challenging Q1 and explained how it would reach its financial targets in the longer term.

Chess_Board_Smoke
Sandoz detailed its strategy, especially for biosimilars • Source: Shutterstock

Sandoz is “now beginning to stabilize” following a challenging start to 2021, with net sales increasing by 11% as reported and 5% in constant currencies to $2.397bn in the second quarter and core operating profit climbing by a tenth as reported to $520m.

Although parent Novartis continues to expect disruptions related to COVID-19 for Sandoz during 2021, “we do also expect healthcare systems to continue on their current trend and return hopefully back to a more stable situation,” Novartis

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Generics Bulletin for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from Earnings

More from Business

‘I’ll Be Happy When We Have 40-Plus Assets’ – Sandoz Builds Up Biosimilars

 
• By Dave Wallace

With biosimilars playing an increasingly important role in Sandoz’s business, the firm’s first-quarter results call saw management lay out the latest key developments. Meanwhile, the company also addressed the issue of US tariffs, voicing optimism over both future developments as well as its ability to weather current measures.

Teva To Slash Thousands Of Jobs And Shut More Sites Under $700m Savings Plan

 
• By Dean Rudge

Teva’s plans to generate net savings of $700m by 2027 have been described by the firm as a journey and not a destination, with the suggestion that “this era of cost efficiency, harmonization, frugality will continue.”

Tetris Deal Falls Into Place For UK’s Aspire

 
• By Dave Wallace

Niche generics company Aspire Pharma has struck a deal to acquire a portfolio of products from fellow UK firm Tetris Pharma as it is wound up, paying Tetris parent Arecor £0.5m for UK distribution rights and inventory.